An innovative drug pipeline is the only defense against new superbugs---novel treatments overcome ABR
Kathy Talkington 16, Pew Charitable Trust Project Director. 12/20/16, “Tracking the Pipeline of Antibiotics in Development” http://www.pewtrusts.org/en/research-and-analysis/collections/2016/12/tracking-the-pipeline-of-antibiotics-in-development
Drug-resistant bacteria, or superbugs, present a serious and worsening threat to human health. A majority of doctors have encountered patients with infections that do not respond to available treatments, and when new drugs come to market bacteria can quickly develop resistance. According to a report from the Centers for Disease Control and Prevention, 2 million Americans acquire serious infections caused by antibiotic-resistant bacteria each year, and at least 23,000 die as a result. A sustained and robust pipeline of new antibacterial drugs and novel therapies is critical to ensure that new interventions keep pace with these evolving pathogens.